MCID: CRY005
MIFTS: 59

Cryptococcosis

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Cryptococcosis

MalaCards integrated aliases for Cryptococcosis:

Name: Cryptococcosis 12 74 52 58 54 43 15 17 32
Infection by Cryptococcus Neoformans 71
Cryptococcus Neoformans Infection 12
Busse-Buschke's Disease 12
European Cryptococcosis 12
Cryptococcal Infection 12
Torulosis 12
Torula 12

Characteristics:

Orphanet epidemiological data:

58
cryptococcosis
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare infectious diseases


Summaries for Cryptococcosis

Disease Ontology : 12 An opportunistic mycosis that results in fungal infection and has material basis in Cryptococcus neoformans or Cryptococcus gattii.

MalaCards based summary : Cryptococcosis, also known as infection by cryptococcus neoformans, is related to cryptococcal meningitis and acquired immunodeficiency syndrome. An important gene associated with Cryptococcosis is SELL (Selectin L), and among its related pathways/superpathways are Innate Immune System and Toxoplasmosis. The drugs Fluconazole and Amphotericin B have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and liver, and related phenotypes are fever and immunodeficiency

Wikipedia : 74 Cryptococcosis, is a potentially fatal fungal disease. It is caused by one of two species; Cryptococcus... more...

Related Diseases for Cryptococcosis

Diseases related to Cryptococcosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 629)
# Related Disease Score Top Affiliating Genes
1 cryptococcal meningitis 32.9 PLB1 MBL2 IFNG CD8A CD4
2 acquired immunodeficiency syndrome 31.5 IFNG FCGR3A CD4 CCR6
3 meningitis 31.3 MBL2 IL4 IFNG FCGR2A
4 meningoencephalitis 31.3 PLB1 CD8A CD4 CCR6
5 cellulitis 31.3 CD8A CD4 CCR6
6 candidiasis 31.1 MBL2 IL4 IFNG CLEC7A
7 lupus erythematosus 31.1 IFNG FCGR3B FCGR3A FCGR2A
8 lymphopenia 31.1 SELL IL4 IFNG CCR6
9 pulmonary tuberculosis 31.0 MBL2 IL4 IFNG
10 immune deficiency disease 30.9 SELL MBL2 IL4 IFNG CD4 CCR6
11 sarcoidosis 1 30.9 IFNG CD8A CD4 CCR6
12 aspergillosis 30.9 MBL2 IL4 IFNG CLEC7A CCR6
13 tularemia 30.9 MBL2 CD8A CD4
14 lymphadenitis 30.9 IFNG CD4 CCR6
15 chorioretinitis 30.8 IFNG CD8A CD4
16 lymph node tuberculosis 30.8 IFNG CD4
17 mucormycosis 30.8 IFNG CLEC7A CD4 CCR6
18 histoplasmosis 30.8 IFNG CLEC7A CD8A CD4 CCR6
19 miliary tuberculosis 30.7 IFNG CD8A CD4
20 neuroretinitis 30.7 IFNG CD4
21 bacterial pneumonia 30.7 CD8A CD4 CCR6
22 penicilliosis 30.7 CLEC7A CD4
23 sporotrichosis 30.5 IFNG CLEC7A CD4
24 pneumocystosis 30.5 CLEC7A CLEC6A CD8A CD4 CCR6
25 allergic hypersensitivity disease 30.5 SELL IL4 IFNG CD4 CCR6
26 crohn's disease 30.4 IL4 IFNG CD4 CCR6
27 pneumonia 30.4 SELL MBL2 IL4 IFNG CD8A
28 coccidioidomycosis 30.4 MBL2 CLEC7A CLEC6A CD4 CCR6
29 esophageal candidiasis 30.4 CD8A CD4 CCR6
30 blastomycosis 30.4 CLEC7A CLEC6A CD8A CD4 CCR6
31 oral candidiasis 30.4 CLEC7A CLEC6A CD8A CD4 CCR6
32 hyper ige recurrent infection syndrome 1 30.3 CLEC7A CD4 CCR6
33 salmonellosis 30.3 IFNG CD8A CD4 CCR6
34 epidermodysplasia verruciformis 1 30.3 CD8A CD4 CCR6
35 thrombocytopenia 30.3 SELL IL4 IFNG FCGR3A FCGR2A
36 pleural disease 30.2 IFNG CD8A CD4 CCR6
37 collagen disease 30.2 IL4 CD8A CD4 CCR6
38 phaeohyphomycosis 30.1 CLEC7A CLEC6A
39 progressive multifocal leukoencephalopathy 30.1 CD8A CD4 CCR6
40 chickenpox 30.1 IL4 IFNG CD8A CD4 CCR6
41 allergic bronchopulmonary aspergillosis 30.1 MBL2 IL4 IFNG
42 invasive aspergillosis 30.1 MBL2 IFNG CLEC7A CLEC6A CD4 CCR6
43 exanthem 30.1 CD8A CD4 CCR6
44 combined t cell and b cell immunodeficiency 30.0 IL4 CD8A CD4 CCR6
45 t cell deficiency 30.0 SELL CD8A CD4 CCR6
46 central nervous system vasculitis 30.0 IFNG CD8A CD4 CCR6
47 pulmonary disease, chronic obstructive 30.0 IL4 CD8A CD4 CCR6
48 dermatophytosis 30.0 CLEC7A CLEC6A CD4 CCR6
49 temporal arteritis 30.0 IFNG CD8A CD4 CCR6
50 cholangitis, primary sclerosing 29.9 CD8A CD4 CCR6

Comorbidity relations with Cryptococcosis via Phenotypic Disease Network (PDN):


Acute Cystitis Cryptococcal Meningitis
Deficiency Anemia

Graphical network of the top 20 diseases related to Cryptococcosis:



Diseases related to Cryptococcosis

Symptoms & Phenotypes for Cryptococcosis

Human phenotypes related to Cryptococcosis:

58 31 (show all 42)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
2 immunodeficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002721
3 cough 58 31 frequent (33%) Frequent (79-30%) HP:0012735
4 nodular pattern on pulmonary hrct 58 31 frequent (33%) Frequent (79-30%) HP:0025392
5 hydrocephalus 58 31 occasional (7.5%) Occasional (29-5%) HP:0000238
6 behavioral abnormality 58 31 occasional (7.5%) Occasional (29-5%) HP:0000708
7 increased intracranial pressure 58 31 occasional (7.5%) Occasional (29-5%) HP:0002516
8 cerebral cortical atrophy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002120
9 vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002013
10 respiratory distress 58 31 occasional (7.5%) Occasional (29-5%) HP:0002098
11 cirrhosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001394
12 chest pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0100749
13 mental deterioration 58 31 occasional (7.5%) Occasional (29-5%) HP:0001268
14 headache 58 31 occasional (7.5%) Occasional (29-5%) HP:0002315
15 meningitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001287
16 pneumonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002090
17 mediastinal lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0100721
18 limb muscle weakness 58 31 occasional (7.5%) Occasional (29-5%) HP:0003690
19 pleural effusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0002202
20 systemic lupus erythematosus 58 31 occasional (7.5%) Occasional (29-5%) HP:0002725
21 nuchal rigidity 58 31 occasional (7.5%) Occasional (29-5%) HP:0031179
22 seizures 58 31 very rare (1%) Very rare (<4-1%) HP:0001250
23 blindness 58 31 very rare (1%) Very rare (<4-1%) HP:0000618
24 memory impairment 58 31 very rare (1%) Very rare (<4-1%) HP:0002354
25 osteomyelitis 58 31 very rare (1%) Very rare (<4-1%) HP:0002754
26 osteolysis 58 31 very rare (1%) Very rare (<4-1%) HP:0002797
27 ophthalmoplegia 58 31 very rare (1%) Very rare (<4-1%) HP:0000602
28 abnormal cranial nerve morphology 58 31 very rare (1%) Very rare (<4-1%) HP:0001291
29 sepsis 58 31 very rare (1%) Very rare (<4-1%) HP:0100806
30 cerebral edema 58 31 very rare (1%) Very rare (<4-1%) HP:0002181
31 peritonitis 58 31 very rare (1%) Very rare (<4-1%) HP:0002586
32 abnormal retinal morphology 58 31 very rare (1%) Very rare (<4-1%) HP:0000479
33 prostatitis 58 31 very rare (1%) Very rare (<4-1%) HP:0000024
34 abnormality of the optic nerve 58 31 very rare (1%) Very rare (<4-1%) HP:0000587
35 abnormality of the outer ear 58 31 very rare (1%) Very rare (<4-1%) HP:0000356
36 vitritis 58 31 very rare (1%) Very rare (<4-1%) HP:0011531
37 lymphoid leukemia 58 31 very rare (1%) Very rare (<4-1%) HP:0005526
38 abnormality of the eye 58 Occasional (29-5%)
39 abnormality of vision 58 Occasional (29-5%)
40 dyspnea 58 Occasional (29-5%)
41 neoplasm 58 Occasional (29-5%)
42 autoimmunity 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Cryptococcosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 CCR6 CD4 CD8A CLEC6A CLEC7A FCGR2A
2 immune system MP:0005387 9.36 CCR6 CD4 CD8A CLEC6A CLEC7A FCGR2A

Drugs & Therapeutics for Cryptococcosis

Drugs for Cryptococcosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 72)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
2
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
3
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
4
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
5
Voriconazole Approved Phase 4 137234-62-9 71616
6
Zidovudine Approved Phase 4 30516-87-1 35370
7
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
8
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
9
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
10
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
11
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
12 Cytochrome P-450 Enzyme Inhibitors Phase 4
13 Steroid Synthesis Inhibitors Phase 4
14 Hormone Antagonists Phase 4
15 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
16 Hormones Phase 4
17 Anti-Bacterial Agents Phase 4
18 Liposomal amphotericin B Phase 4
19 Antiparasitic Agents Phase 4
20 Antiprotozoal Agents Phase 4
21 Cytochrome P-450 CYP3A Inhibitors Phase 4
22 Reverse Transcriptase Inhibitors Phase 4
23 Anti-Retroviral Agents Phase 4
24 Anti-HIV Agents Phase 4
25 Antiviral Agents Phase 4
26 Cytochrome P-450 CYP3A Inducers Phase 4
27 Trace Elements Phase 4
28 Vitamins Phase 4
29 Ergocalciferols Phase 4
30 Micronutrients Phase 4
31 Nutrients Phase 4
32 Vitamin D2 Phase 4
33 Calciferol Phase 4
34 Calcium, Dietary Phase 4
35
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
36
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
37
Posaconazole Approved, Investigational, Vet_approved Phase 3 171228-49-2 147912
38
Isavuconazole Approved, Investigational Phase 3 241479-67-4
39
Sertraline Approved Phase 3 79617-96-2 68617
40 Pharmaceutical Solutions Phase 3
41
Hydroxyitraconazole Phase 3
42 Neurotransmitter Agents Phase 3
43 Serotonin Uptake Inhibitors Phase 3
44 Psychotropic Drugs Phase 3
45 Serotonin Agents Phase 3
46 Antidepressive Agents Phase 3
47
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
48
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
49
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
50
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189

Interventional clinical trials:

(show all 47)
# Name Status NCT ID Phase Drugs
1 Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex at 10 mg/kg/d for 7 Days or 5.0 mg/kg/d for 14 Days as Induction Therapy for Disseminated Cryptococcosis in Patients With HIV Completed NCT01656382 Phase 4 ABLC
2 Operational Research for Cryptococcal Antigen Screening to Improve ART Survival Completed NCT01535469 Phase 4 Fluconazole
3 Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis Completed NCT01075152 Phase 4 efavirenz
4 Prospective Double Blind Multicentre Randomized Trial of Vitamine D Estimating the Profit of a Treatment by Vitamin D3 at the Dose of 100000 UI by Comparison With a Treatment in the Dose of 12 000 UI at Renal Transplanted Patients Completed NCT01431430 Phase 4 Cholecalciferol 100 000 UI;Cholecalciferol 12 000 UI
5 An Open Label, Non-comparative, Multicenter Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infection Completed NCT00647907 Phase 4 Voriconazole
6 Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis. Open Label Phase III Clinical Study Unknown status NCT01125644 Phase 3 SPK-843
7 Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081) Completed NCT00000676 Phase 3 Clotrimazole;Fluconazole
8 A Pharmacokinetic Study of JK1211 in Patients With Systemic Fungal Infection (SFI) and Patients With Febrile Neutropenia (FN) Suspected of Fungal Infection. Completed NCT00784368 Phase 3 ITCZ Oral Solution;ITCZ-IV
9 Open Label, Treatment Protocol for the Safety and Efficacy of Posaconazole (SCH 56592) in the Treatment of Invasive Fungal Infections Completed NCT00034658 Phase 3 Posaconazole
10 Comparison of Fluconazole (UK-49,858) and Amphotericin B for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00001017 Phase 3 Fluconazole;Amphotericin B
11 Open Label, Treatment Protocol for the Safety and Efficacy of Posaconazole (SCH 56592) in the Treatment of Invasive Fungal Infections Completed NCT00034632 Phase 3 Posaconazole oral suspension
12 A Phase 3, Multi-center, Open Label Study to Evaluate Safety and Efficacy of AK1820 for Treatment of Adult Japanese Patients With Deep Mycosis Recruiting NCT03471988 Phase 3 AK1820;Voriconazole
13 Cryptococcal Antigen Screening Plus Sertraline Terminated NCT03002012 Phase 3 Sertraline;Placebo Oral Tablet;Fluconazole
14 Dexamethasone in Cryptococcal Meningitis Completed NCT00000776 Phase 2 Flucytosine;Fluconazole;Amphotericin B;Dexamethasone
15 Phase II Study of Safety, Tolerance, Efficacy, and Pharmacokinetics of Posaconazole (SCH 56592) for the Treatment of Invasive Fungal Infections in Immunocompromised Hosts Completed NCT00034671 Phase 2 Posaconazole oral suspension
16 An Open Label Randomized Controlled Phase IIb Trial to Determine the Safety of Oral Fluconazole in Combination With Flucytosine as Compared to Fluconazole Alone Terminated NCT01562132 Phase 2 Flucytosine and fluconazole;Fluconazole
17 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Mycograb® as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS Terminated NCT00324025 Phase 2 Mycograb;placebo
18 A Prospective Cohort to Evaluate the Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB/MAT2203) for the Treatment of Cryptococcal Infection Withdrawn NCT03196921 Phase 1, Phase 2 Encochleated Amphotericin B
19 SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy Completed NCT00000677 Phase 1 SCH 39304
20 Multi-center Clinical Trial of Pulmonary Cryptococcosis in China Unknown status NCT02503449
21 Vietnam Cryptococcal Retention in Care Study (CRICS) - Version 2.1 Unknown status NCT03267407
22 Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection Completed NCT00001701
23 Analysis of Clinical and Immunological Characteristics, as Well as Pathophysiological Mechanisms in a French Cohort of Patients With Idiopathic CD4 Lymphocytopenia Completed NCT02113930
24 Special Investigation Of Fluconazole For Pediatric Subjects Completed NCT01680458 Fluconazole
25 Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002076 Fluconazole
26 Multi-Center Evaluation of Fluconazole (UK-49,858) as Treatment for Acute Cryptococcal Meningitis in Patients Who Have Failed to Respond or Have Experienced Unacceptable Toxicity During Treatment With Amphotericin B Completed NCT00002306 Fluconazole
27 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002305 Flucytosine;Fluconazole;Amphotericin B
28 Double Blind Placebo Controlled Study of Fluconazole (UK-49,858) for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00002294 Fluconazole
29 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002075 Flucytosine;Fluconazole;Amphotericin B
30 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00002074 Fluconazole;Amphotericin B
31 A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002068 Fluconazole;Amphotericin B
32 Randomized Study Comparing Itraconazole to Placebo in the Prevention of Histoplasmosis in Patients With Human Immunodeficiency Virus Infection Completed NCT00002438 Itraconazole
33 An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002077 Fluconazole
34 Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002040 Fluconazole
35 Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome Completed NCT00002019 Amphotericin B, Lipid-based;Amphotericin B
36 Randomized Control Trial of Early vs Delayed ART in the Treatment of Cryptococcal Meningitis. Completed NCT00830856 Fluconazole;Fixed dose - Stavudine, lamivudine and Nevirapine;Fixed dose - Stavudine, Lamivudine, Nevirapine
37 A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis. Completed NCT00002113 Flucytosine;Fluconazole
38 A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00000639 Itraconazole;Flucytosine;Fluconazole;Amphotericin B
39 Plasma Nevirapine Levels and Adverse Events Among HIV-Infected Patients Concurrently Receiving Nevirapine-Based Antiretroviral Therapy and Fluconazole Completed NCT00309582
40 A Cohort Observational Study Evaluating Predictors, Incidence and Immunopathogenesis of Immune Reconstitution Syndrome (IRIS) in HIV-1 Infected Patients With CD4 Count Less Than or Equal to 100 Cells/microL Who Are Initiating Antiretroviral Therapy Completed NCT00286767
41 Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00000708 Flucytosine;Fluconazole;Amphotericin B
42 AIDS-Associated Heart Disease -- Incidence and Etiology Completed NCT00005228
43 Cryptococcosis in Previously Healthy Adults Recruiting NCT00001352
44 AIDS Defining Opportunistic Infections in Naive HIV Cases Recruiting NCT03993093
45 Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models Recruiting NCT02015013
46 Vicente Ferrer HIV Cohort Study Recruiting NCT02454569
47 Making an Early Diagnosis of Talaromycosis - a Strategy to Reduce Morbidity and Mortality in Advanced HIV Disease in Southeast Asia Not yet recruiting NCT04033120

Search NIH Clinical Center for Cryptococcosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Itraconazole

Cochrane evidence based reviews: cryptococcosis

Genetic Tests for Cryptococcosis

Anatomical Context for Cryptococcosis

MalaCards organs/tissues related to Cryptococcosis:

40
Lung, Testes, Liver, Skin, Brain, T Cells, Bone

Publications for Cryptococcosis

Articles related to Cryptococcosis:

(show top 50) (show all 4957)
# Title Authors PMID Year
1
Levels of L-selectin (CD62L) on human leukocytes in disseminated cryptococcosis with and without associated HIV-1 infection. 61 54
15776384 2005
2
Complications of therapeutic plasma exchange: A retrospective study of 1201 procedures in 435 children. 61
31852113 2019
3
The mitochondrial intergenic regions nad1-cob and cob-rps3 as molecular identification tools for pathogenic members of the genus Cryptococcus. 61
31665278 2019
4
Effect of infectious disease consultation on mortality and treatment of patients with candida bloodstream infections: a retrospective, cohort study. 61
31562024 2019
5
Genotypic diversity in clinical and environmental isolates of Cryptococcus neoformans from India using multilocus microsatellite and multilocus sequence typing. 61
31820495 2019
6
Basic principles of the virulence of Cryptococcus. 61
31119976 2019
7
High Prevalence of Cryptococcus neoformans and Isolation of Other Opportunistic Fungi From Pigeon (Columba livia) Droppings in Northeast Iran. 61
31833301 2019
8
A Mechanosensitive Channel Governs Lipid Flippase-Mediated Echinocandin Resistance in Cryptococcus neoformans. 61
31822582 2019
9
Did This Cryptococcosis Patient Have HIV Coinfection? 61
31391390 2019
10
Standard antifungal therapy for pulmonary cryptococcosis to improve prognosis. 61
31782387 2019
11
The Author's Reply to "Did This Cryptococcosis Patient Have HIV Coinfection?" 61
31391397 2019
12
Standard antifungal therapy for pulmonary cryptococcosis to improve prognosis - Authors' reply. 61
31782386 2019
13
Efficacy of voriconazole in vitro and in invertebrate model of cryptococcosis. 61
31832690 2019
14
Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia. 61
31741032 2019
15
Clinical spectrum and outcome of hospitalized patients with invasive fungal infections: a prospective study from a medical ward/intensive care unit of a teaching hospital in North India. 61
31846989 2019
16
An AIDS patient with urine retention. 61
31830905 2019
17
Concomitant lung adenocarcinoma and pulmonary cryptococcosis confirmed by pathologic examinations. 61
31852116 2019
18
The Disease Ecology, Epidemiology, Clinical Manifestations, and Management of Emerging Cryptococcus gattii Complex Infections. 61
31813737 2019
19
Cryptococcus neoformans seropositivity and some haematological parameters in HIV seropositive subjects. 61
31831399 2019
20
New Triazole NT-a9 has Potent Antifungal Efficacy against Cryptococcus neoformans In Vitro and In Vivo. 61
31791946 2019
21
Effects of CD4 cell count and antiretroviral therapy on mucocutaneous manifestations among HIV/AIDS patients in Yunnan, China. 61
31846069 2019
22
A Highly Active Triterpene Derivative Capable |of Biofilm Damage to Control Cryptococcus spp. 61
31817559 2019
23
A Heat-Killed Cryptococcus Mutant Strain Induces Host Protection against Multiple Invasive Mycoses in a Murine Vaccine Model. 61
31772051 2019
24
Proteomics of Rat Lungs Infected by Cryptococcus gattii Reveals a Potential Warburg-like Effect. 61
31502459 2019
25
Clinical significance of low serum cryptococcal antigen titers by lateral flow assay in immunocompromised patients: a retrospective case control study. 61
31723013 2019
26
Regulatory Mechanism of the Atypical AP-1-Like Transcription Factor Yap1 in Cryptococcus neoformans. 61
31748248 2019
27
Clinical diversity of invasive cryptococcosis in AIDS patients from central China: report of two cases with review of literature. 61
31775716 2019
28
Patterns of allele distribution in a hybrid population of the Cryptococcus neoformans species complex. 61
31774582 2019
29
Protection of mice against experimental cryptococcosis using glucan particle-based vaccines containing novel recombinant antigens. 61
31699504 2019
30
Cryptococcal antigenemia prevalence and clinical data in HIV-infected patients from the reference centre at INI-FIOCRUZ, Rio de Janeiro, Southeast of Brazil. 61
31715053 2019
31
Cryptococcal Antigenemia in HIV therapy-experienced Ugandans with Virologic Failure. 61
31679007 2019
32
Incidence and clinical outcome of Cryptococcosis in a nation with advanced HIV surveillance program. 61
31741419 2019
33
Are macrophages the heroes or villains during cryptococcosis? 61
31415906 2019
34
[Diagnostic performance of pathology, culture and ROSE of lung biopsy for suspected pulmonary infectious diseases]. 61
31715672 2019
35
Identification of the environmental source of infection for a domestic ferret with cryptococcosis. 61
31551015 2019
36
Immune reconstitution inflammatory syndrome in the lung in non-human immunodeficiency virus patients. 61
31791908 2019
37
Invasive Fungal Infections With Good Survival Following Liver Transplant: A Single-Center Experience From a Developing Country. 61
31724926 2019
38
Opportunistic invasive fungal disease in patients with type 2 diabetes mellitus from Southern China: clinical features and associated factors. 61
31758642 2019
39
Neutrophil-mediated antifungal activity against highly virulent Cryptococcus gattii strain R265. 61
30668754 2019
40
Molecular epidemiology and antifungal susceptibility profiles of clinical Cryptococcus neoformans/Cryptococcus gattii species complex. 61
31750814 2019
41
Photodynamic therapy inhibits cell growth and enhances the histone deacetylase-mediated viability impairment in Cryptococcus spp. in vitro. 61
31731064 2019
42
Modulation of host immune status by cryptococcus co-infection during HIV-1 pathogenesis and its impact on CD+4 cell and cytokines environment. 61
31715319 2019
43
The significance of anti-granulocyte-macrophage colony-stimulating factor antibodies in cryptococcal infection: case series and review of antibody testing. 61
31713345 2019
44
Very early-onset of Cryptococcus neoformans disease following liver transplantation: Report of two cases and a review of the literature. 61
31785187 2019
45
Incidence of and risk factors for cryptococcosis in kidney transplant recipients in Taiwan-A nationwide population-based study. 61
31449926 2019
46
Successful treatment with voriconazole combined with amphotericin B-liposome for fluconazole-resistant pulmonary cryptococcosis after renal transplantation. 61
31161376 2019
47
Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model. 61
31420668 2019
48
Clinical insights and epidemiology of central nervous system infection due to Cryptococcus neoformans/gattii species complexes: A prospective study from South India. 61
31578566 2019
49
Prevalence of cryptococcal antigenemia and nasal colonization in a free-ranging koala population. 61
30649397 2019
50
Cryptococcus neoformans pericarditis in a lung transplant recipient: Case report, literature review and pearls. 61
31267603 2019

Variations for Cryptococcosis

Expression for Cryptococcosis

Search GEO for disease gene expression data for Cryptococcosis.

Pathways for Cryptococcosis

Pathways related to Cryptococcosis according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 SELL MBL2 IL4 IFNG FCGR3B FCGR3A
2
Show member pathways
12.08 IL4 IFNG FCGR3B FCGR3A FCGR2A
3 12.02 IFNG FCGR3B FCGR3A FCGR2A CLEC7A
4 11.92 IFNG FCGR3B FCGR3A FCGR2A
5 11.9 MBL2 FCGR3B FCGR3A FCGR2A CLEC7A
6
Show member pathways
11.85 IL4 IFNG CD8A CD4
7
Show member pathways
11.76 IL4 IFNG FCGR3B FCGR3A FCGR2A
8 11.74 IL4 CD8A CD4
9 11.74 MBL2 FCGR3B FCGR3A FCGR2A
10 11.7 FCGR3B FCGR3A FCGR2A
11 11.65 FCGR3B FCGR2A CLEC7A
12 11.6 SELL IFNG CD8A CD4
13 11.46 IL4 IFNG CD8A CD4 CCR6
14 11.38 IL4 IFNG CD4
15 11.2 IL4 IFNG FCGR3B FCGR3A FCGR2A
16 11.16 SELL IL4 IFNG FCGR2A CD8A CD4
17 11.12 IL4 IFNG CD4

GO Terms for Cryptococcosis

Cellular components related to Cryptococcosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.02 SELL FCGR3A CD8A CD4 CCR6

Biological processes related to Cryptococcosis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 regulation of immune response GO:0050776 9.76 SELL IL4 FCGR3A CD8A
2 hormone-mediated signaling pathway GO:0009755 9.58 CGB8 CGB7 CGB3
3 positive regulation of phagocytosis GO:0050766 9.5 MBL2 IFNG CLEC7A
4 immune response GO:0006955 9.5 IL4 IFNG FCGR3B FCGR3A CD8A CD4
5 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.49 CLEC7A CD4
6 positive regulation of MHC class II biosynthetic process GO:0045348 9.48 IL4 IFNG
7 positive regulation of killing of cells of other organism GO:0051712 9.43 IFNG CLEC7A
8 neuroinflammatory response GO:0150076 9.37 IL4 IFNG
9 female gamete generation GO:0007292 9.33 CGB8 CGB7 CGB3
10 positive regulation of cellular respiration GO:1901857 9.26 IL4 IFNG
11 T cell activation GO:0042110 8.92 IL4 CLEC7A CD8A CD4

Molecular functions related to Cryptococcosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 9.26 SELL MBL2 CLEC7A CLEC6A
2 IgG binding GO:0019864 8.8 FCGR3B FCGR3A FCGR2A

Sources for Cryptococcosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....